Autologous bone marrow transplantation in decompensated liver: Systematic review and meta-analysis

Table 1 Most patients in the included studies had hepatitis virus infection and/or high alcohol consumption, and suffered from decompensate liver cirrhosis

Trials	Region	Design	Duration	No. of patients	Etiology of liver disease	Intervention	Follow-up
Lyra 2010	Brazil	RCT	2006.1-2006.4	15 vs 15	Chronic liver disease waiting for liver transplantation, mainly alcoholic and/or hepatitis C	About 3.78 × 108 BM-MNCs, through hepatic artery	Up to 12 mo
Salama 2010	Egypt	RCT	2008.6-2009.5	90 vs 50	Post-HCV liver cirrhosis	Autologous BM-derived CD34+ and CD133+ stem cell infusion in the portal vein	Up to 6 mo
Spahr 2012	Switzerland	RCT	2008.2-2011.3	28 vs 30	Decompensated alcoholic liver disease	About 4.7 × 107/kg BM-MNCs, including CD34+ cells and MSCs	Up to 3 mo
Mohanmadnejad 2013	Iran	RCT	2007.7-2010.8	15 vs 12	2 PBC, 2 HBV, 1 HCV, 9 AIH, 11 unknown	About 1.95 × 108 MSCs through cubital vein	Up to 12 mo
Bai 2004	China	Case-control	2009.3-2011.3	32 vs 15	Decompensated liver cirrhosis, 91.5% with HBV infection	BM-MNCs through hepatic artery	Up to 24 mo
Peng 2011	China	Case-control	2005.5-2009.6	53 vs 105	Chronic hepatitis B induced liver disease, 73% with cirrhosis	BM-derived MSCs through proper hepatic artery	Up to 192 wk
Saito 2011	Japan	Case-control	NA	5 vs 5	Alcoholic liver cirrhosis	About 8 × 109 BM-MNCs through cubital vein	Up to 48 wk
El-Ansary 2012	Egypt	Prospective cohort study	NA	15 vs 10	HCV induced liver cirrhosis	About 1 × 106 MSCs/kg, intravenously	Up to 6 mo

PBC: Primary biliary cirrhosis; HBV: Hepatitis B virus; HCV: Hepatitis C virus; AIH: Autoimmune hepatitis; BM-MNCs: Bone marrow mononuclear cells; MSC: Mesenchyme stem cell; RCT: Randomized controlled trial; NA: Not available.